春立医疗(688236) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 107.824 million and 127.824 million yuan, a decrease of 150 million to 170 million yuan compared to the previous year, representing a year-on-year decline of 53.99% to 61.19%[3] - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses is expected to be between 79.1283 million and 99.1283 million yuan, a decrease of 155 million to 175 million yuan compared to the previous year, representing a year-on-year decline of 60.99% to 68.86%[3] - The previous year's net profit attributable to shareholders of the parent company was 277.824 million yuan, and the net profit after deducting non-recurring gains and losses was 254.1283 million yuan[5] - The company’s earnings per share for the previous year was 0.72 yuan[6] Factors Affecting Profit - The decline in profit is primarily due to the ongoing impact of centralized procurement policies, which led to a decrease in product prices and gross margins[7] - The company adjusted prices for channel inventory prior to centralized procurement implementation, resulting in decreased revenue and net profit[7] Procurement Success and Forecast Accuracy - The company successfully won bids for all joint products in the national centralized procurement and for all sports medicine products in the relevant procurement categories[7] - As of the announcement date, the company has not identified any significant uncertainties affecting the accuracy of the earnings forecast[8] - The forecast data is preliminary and the final audited financial data will be disclosed in the 2024 annual report[9]